Pharmacopsychiatry 2011; 44(7): 343
DOI: 10.1055/s-0031-1295450
Erratum

© Georg Thieme Verlag KG Stuttgart · New York

Long-Term Assessment of Asenapine vs. Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder

J. Schoemaker1 , D. Naber2 , P. Vrijland1 , J. Panagides3 , R. Emsley4
  • 1Schering-Plough (formerly NV Organon), now Merck Sharp & Dohme, Oss, The Netherlands
  • 2University of Hamburg-Eppendorf, Hamburg, Germany
  • 3Schering-Plough (formerly Organon), now Merck, Summit, New Jersey, USA
  • 4University of Stellenbosch, Cape Town, South Africa
Further Information

Publication History

Publication Date:
17 November 2011 (online)

Erratum

J. Schoemaker, D. Naber, P. Vrijland, J. Panagides, R. Emsley

Long-Term Assessment of Asenapine vs. Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder Pharmacopsychiatry 2010; 43: 138–146

Pharmacopsychiatry 2010; 43: 138–146 DOI: 10.1055/s-0030-1248313

On p. 141, there are errors that incorrectly identify the figures which present weight gain data. The text “At week 52, using observed case data, mean ± SD change was l.6 ± 5.7 kg (3.5 ± 12.6 Ibs) for asenapine and 5.6 ± 8.4 kg (12.3 ± 18.5 lbs) for olanzapine (Fig. 3a). At endpoint, using LOCF data from all treated patients, mean ± SD changes were 0.9 ± 4.8kg (2.0 ± 10.6 Ibs) and 4.2 ± 7.6 kg (9.2 ± 16.8 Ibs), respectively (Fig. 3b).” should be “At endpoint, using LOCF data from all treated patients, mean ± SD changes were 0.9 ± 4.8 kg (2.0 ± 10.6 Ibs) and 4.2 ± 7.6 kg (9.2 ± 16.8 Ibs), respectively (Fig. 3a). At week 52, using observed case data, mean ± SD change was l.6 ± 5.7 kg (3.5 ± 12.6 Ibs) for asenapine and 5.6 ± 8.4 kg (12.3 ± 18.5 lbs) for olanzapine (Fig. 3b).”

On p. 144, the text in the legend for figure 3 noting “Weight change over time in the safety population. A. OC analysis. B. Last observations carried forward (LOCF) analysis.” should be “Weight change over time in the safety population. A. Last observations carried forward (LOCF) analysis. B. OC analysis.”

    >